

## DORSET MEDICINES ADVISORY GROUP Recommendation Summary

The Dorset Medicines Advisory Group (DMAG) includes representatives from the four provider Trusts, Public Health Dorset and GPs within the NHS Dorset Integrated Care Board. It advises the system on prescribing and commissioning of medicines in Dorset.

Summary of recommendations made by the group March 2023. Formulary entries and associated documents can be accessed at [www.dorsetformulary.nhs.uk](http://www.dorsetformulary.nhs.uk).

PRODUCT	DECISION		COMMENTS
1. Products re-categorised	Previous position	Recommended position	
Famotidine	Non-Formulary	Green	To support patients requiring an H2 -receptor antagonists due to the discontinuation of ranitidine.
Nizatidine	Non-Formulary	Green	To support patients requiring an H2 -receptor antagonists due to the discontinuation of ranitidine.
Cimetidine	Amber	Green	To support patients requiring an H2 -receptor antagonists due to the discontinuation of ranitidine.
Accu-chek® Performa	Green	Non-Formulary	The blood glucose test strips guidance for Type 2 diabetes has been revised to include newer options and cost-effective products.
Contour® One Touch	Green	Non-Formulary	The blood glucose test strips guidance for Type 2 diabetes has been revised to include newer options and cost-effective products.
MyLife® Pura	Green	Non-Formulary	The blood glucose test strips guidance for Type 2 diabetes has been revised to include newer options and cost-effective products.

PRODUCT	DECISION		COMMENTS
MyLife® Unio	Green	Non-Formulary	The blood glucose test strips guidance for Type 2 diabetes has been revised to include newer options and cost-effective products.
Venturi Connector®	Amber	Non- Formulary	Discontinued by manufacturer
Venturi wound sealing kit with flat drain large®	Amber	Non- Formulary	Discontinued by manufacturer
Venturi wound sealing kit with flat drain standard®	Amber	Non- Formulary	Discontinued by manufacturer
Venturi adhesive gel patch®.	Amber	Non- Formulary	Discontinued by manufacturer
<b>2. New requests</b>			
Oral hydralazine	Amber		In line with NICE NG106 as a 2 <sup>nd</sup> or 3 <sup>rd</sup> line option in combination with nitrates for patients with heart failure with reduced ejection fraction who cannot tolerate an ACE inhibitor or ARBs.
Prucalopride tablets	Red		New request within UHDFT drug and therapeutics committee, added as part of the Colon Capsule Endoscopy protocol for bowel-preparation for adult patients with chronic constipation or those with a past history of poor bowel cleansing for colonoscopy.
Ferric Derisomaltose (iron isomaltoside, Monofer®) injection/infusion	Red		New request within UHDFT drug and therapeutics committee, for adults with iron deficiency and heart failure with or without anaemia.
Alteplase (Actilyse®)	Red		New request within DCH and UHDFT drug and therapeutics committee, for the management of pleural infection resistant to 1 <sup>st</sup> line therapies.
Dornase Alfa (Pulmozyme®)	Red		New request within DCH and UHDFT drug and therapeutics committee, for the management of pleural infection resistant to 1 <sup>st</sup> line therapies.
IQoro®	Non-formulary Black		A neuromuscular training device used for improving symptoms related to hiatus hernia by strengthening the oesophagus and diaphragm.

PRODUCT	DECISION	COMMENTS
Indwelling Pleural Catheter (IPC) dressing packs (PleurX® & Rocket®)	Non-formulary Black	Not to be issued from Primary Care. For patients discharged from secondary care with an IPC drain, supplies are to be ordered directly through Dorset Health Care's procurement team.
Renasys® Adhesive gel	Amber	Added as a temporary alternative due to the discontinuation of Venturi® Adhesive Gel patch. A long-term replacement will be decided when a full review is carried out.
Upadacitinib	Red	In line with NICE TA861.
Somatrogon	Red	In line with NICE TA863.
Eptinezumab	Red	In line with NICE TA871.
Semaglutide (Wegovy®)	Red	In line with NICE TA875. Wegovy® supplies are not currently available and local commissioning arrangements are being clarified therefore it is not currently possible to provide a timescale for implementation.
Accu chek® Instant	Green	Cost effective option for Type 2 diabetes. The blood glucose test strips guidance for Type 2 diabetes has been revised to include newer options and cost-effective products.
Contour plus® Blue	Green	Cost effective option for Type 2 diabetes. The blood glucose test strips guidance for Type 2 diabetes has been revised to include newer options and cost-effective products.
Gluco Rx® Vivid	Green	Cost effective option for Type 2 diabetes. The blood glucose test strips guidance for Type 2 diabetes has been revised to include newer options and cost-effective products.
Gluco Rx HCT	Green	Cost effective option for Type 2 diabetes. The blood glucose test strips guidance for Type 2 diabetes has been revised to include newer options and cost-effective products.
<b>3. Products considered by NICE</b>		
<p><a href="#">NICE TA861</a> Upadacitinib for treating active non-radiographic axial spondyloarthritis</p> <p><a href="#">NICE TA863</a> Somatrogon for treating growth disturbance in children and young people aged 3 years and over.</p> <p><a href="#">NICE TA871</a> Eptinezumab for preventing Migraine.</p> <p><a href="#">NICE TA875</a> Semaglutide (Wegovy®) for managing overweight and obesity.</p>		

PRODUCT	DECISION	COMMENTS
<b>4. Miscellaneous recommendations by DMAG</b>		
Allevyn Gentle®	Approved to extend the addition on the formulary to Autumn 2023	For a full neutral evaluation.
Brivaracetam	Formulary entry amendment	A small amendment to the terminology would enable Brivaracetam to be used in preference to levetiracetam where there is a clinical concern about the use of levetiracetam. It is therefore approved to add “or where the patient has significant mental health issues for which it may be preferred over levetiracetam”.
Verapamil	Addition of NICE-CKS, BASH leaflet and UKMI information links for verapamil in cluster headache to a formulary entry as a “green” drug	Approved to support initiation of treatment in primary care by following the diagnosis and management guideline of NICE-CKS for cluster headache. If diagnosis not yet confirmed by secondary care, seek advice and make referral to secondary care prior to initiation. Agreed to add this treatment to the formulary for this indication with a green rating in Sept 22 in accordance with NICE CG150. It was agreed to add links to the NICE-CKS/ BASH guideline/ UKMI document to support prescribing and monitoring.
Low Molecular Weight Heparin FAQ	Retired from the formulary	
Pevanti® Commissioning Statement	Retired from the formulary	Due to no prescribing in Dorset.
Cimetidine 800mg and ranitidine 150mg and 300mg	Discontinued by manufacturer	The SystmOne formulary and the Dorset formulary have been updated to reflect this.
IV pantoprazole	The entry has been updated to remove the supply issue message.	
Peristeen® Plus	Entry updated to remove messaging regarding the discontinuation of Peristeen®.	

PRODUCT	DECISION	COMMENTS
Pancreatin	Entry updated to remove the June 2019 message relating to the discontinuation of Creon® 40,000. To support dosing of 40,000 units the following statement was approved to be added “If unable to give 40,000 dose units please replace with 25,000 units with the aim to round up a dose rather than round down”.	
SPS UKMI documents for chapter 1	The following UKMI documents were noted as updated within chapter 1	<a href="#">UKMI Q&amp;A: Using Proton Pump Inhibitors (PPIs) alongside warfarin – clinical considerations</a>  <a href="#">UKMI Q&amp;A: High dose loperamide use in high stoma output or short bowel syndrome</a>  <a href="#">UKMI Prescribing in lactose intolerance and how to identify lactose free medicines</a>
<b>5. Further Assessment / Evidence Required</b>		
Pain Working Group Terms of reference and Tapentadol Shared Care Guideline	Paused until the next DMAG meeting, where the working group chair would be invited to present the ToR and the chronic pain pathway.	
<b>6. New documents approved</b>		
<ul style="list-style-type: none"> <li>• National Shared care protocols for dronedarone.</li> <li>• National Shared care protocols for amiodarone.</li> </ul>		

PRODUCT	DECISION	COMMENTS
<ul style="list-style-type: none"> <li>• Inclisiran FAQ.</li> <li>• Prescribable Continuous Glucose Monitoring (CGM): Type 2 diabetes prescribable CGM pathway in primary care.</li> <li>• Local guidance for the safe use of sodium glucose Co-transporter 2 (SGLT2) inhibitors in patients with type 2 diabetes.</li> <li>• IQoro® Commissioning statement.</li> <li>• Eptinezumab for preventing migraine (NICE TA871) commissioning statement.</li> <li>• Somatrogen for treating growth disturbance in people 3 years and over (NICE TA863) commissioning Statement.</li> <li>• Upadacitinib for treating active non-radiographic axial spondyloarthritis (NICE TA861) commissioning Statement.</li> <li>• Oscillating Positive Expiratory Pressure (OPEP) adjunct devices Commissioning statement.</li> <li>• Great Green Respiratory Care – One-page Summary (NHS Dorset Green Inhaler Prescribing Guidance).</li> </ul>		
<p><b>7. Documents Reviewed</b></p>		
<ul style="list-style-type: none"> <li>• DOACs in Obesity.</li> <li>• rtCGM for patients 2 years and older with Type 1 diabetes, Type 2 diabetes &amp; Type 3c diabetes in restricted circumstances Commissioning Statement.</li> <li>• Prescribable Continuous Glucose Monitoring (CGM): Frequently Asked Questions.</li> <li>• Prescribable Continuous Glucose Monitoring (CGM): Shared Decision-Making Tool.</li> <li>• Prescribable Continuous Glucose Monitoring (CGM): SystmOne Protocol.</li> <li>• Glucose test strip formulary for Type 2 diabetes.</li> <li>• Pan Dorset Wound Care Formulary.</li> <li>• Diabetes Foot Wound Care Formulary and Anti-Microbial Management.</li> <li>• Joint Wound Formulary feedback form.</li> <li>• Joint Wound Formulary Rationale for prescribing non-formulary wound product.</li> <li>• Migraine Pathway.</li> <li>• Risks associated with Gabapentinoids guidance.</li> <li>• Pathway for the use of biologics for axial spondyloarthritis.</li> <li>• DOAC initiation checklist (version 10).</li> <li>• Ivabradine in chronic heart failure commissioning statement.</li> <li>• Bempedoic acid with Ezetimibe commissioning statement.</li> <li>• Rivaroxaban in CAD or PAD commissioning statement.</li> <li>• Ticagrelor for preventing Atherothrombotic events after Myocardial Infarction and for the treatment of Acute Coronary Syndromes commissioning statement.</li> </ul>		

PRODUCT	DECISION	COMMENTS
<ul style="list-style-type: none"> <li>• High-Cost Inflammatory Bowel Disease Pathway (Version 3).</li> <li>• In Focus PPI deprescribing guidance.</li> <li>• Tofacitinib for ulcerative colitis (NICE TA547) Commissioning Statement.</li> <li>• Vedolizumab for active Ulcerative Colitis (NICE TA352) Commissioning Statement.</li> <li>• Vedolizumab for active Crohn’s (NICE TA352) Commissioning Statement.</li> <li>• Budesonide for eosinophilic oesophagitis (Jorveza®) (NICE TA708) Commissioning Statement.</li> <li>• Andexanet alfa (Ondexxa®) (NICE TA697) Commissioning Statement.</li> <li>• Pharmacological management of Parkinson’s Disease.</li> <li>• Impulsive and compulsive behaviour in Parkinson’s monitoring and information tool.</li> <li>• Dopamine agonists shared care guideline.</li> <li>• Selegiline and Rasagiline shared care guideline.</li> <li>• Entacapone and Opicapone shared care guideline.</li> <li>• Amantadine shared care guideline.</li> <li>• Buccal midazolam shared care guideline for adults.</li> <li>• Galcanezumab for Preventing Chronic or Episodic Migraine (NICE TA659) Commissioning Statement.</li> <li>• Erenumab for Preventing Chronic or Episodic Migraine (NICE TA682) Commissioning Statement.</li> </ul>		

Classification of products:

‘RED’ drugs for hospital use only.

‘AMBER with shared care’ drugs suitable for use on specialist advice with shared care arrangements

‘AMBER’ drugs suitable for use on specialist advice without shared care arrangements

‘GREEN’ drugs suitable for prescribing in primary and secondary care.

‘Not Recommended’ – drugs not recommended for use in Dorset.